0001144204-14-037856.txt : 20140624 0001144204-14-037856.hdr.sgml : 20140624 20140616160255 ACCESSION NUMBER: 0001144204-14-037856 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20140612 FILED AS OF DATE: 20140616 DATE AS OF CHANGE: 20140616 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celator Pharmaceuticals Inc CENTRAL INDEX KEY: 0001327467 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 303B COLLEGE ROAD EAST CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: (609) 243-0123 MAIL ADDRESS: STREET 1: 303B COLLEGE ROAD EAST CITY: PRINCETON STATE: NJ ZIP: 08540 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MOLLICA JOSEPH A CENTRAL INDEX KEY: 0001126489 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36179 FILM NUMBER: 14922798 MAIL ADDRESS: STREET 1: 10555 SCIENCE CENTER DR CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 v381465_4.xml FORM 4 X0306 4 2014-06-12 0 0001327467 Celator Pharmaceuticals Inc CPXX 0001126489 MOLLICA JOSEPH A C/O CELATOR PHARMACEUTICALS, INC. 200 PRINCETONSOUTH CORP. CENTER, STE 180 EWING NJ 08628 1 0 0 0 Stock Option (right to buy) 2.80 2014-06-12 4 A 0 14000 0 A 2024-06-12 Common Stock 14000 14000 D The options vests as follows: (i) 4,666 options vest on June 12, 2015; (ii) the remaining 9,334 shares vest in seven consecutive quarterly installments of 1,166 shares each on the 12th day of each respective month, beginning September 12, 2015 and continuing through March 12, 2017 with a final installment of 1,172 shares on June 12, 2017. Exhibit List - Exhibit 24 - Confirming Statement /s/ Fred M. Powell, attorney in fact 2014-06-16 EX-24 2 v381465_ex24.htm EXHIBIT 24

EXHIBIT 24

CONFIRMING STATEMENT

This Statement confirms that the undersigned, Joseph A. Mollica, has authorized and designated Scott T. Jackson and Fred M. Powell, signing singly, to execute and file on the undersigned’s behalf all Forms 3, 4 and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned’s ownership of or transactions in securities of Celator Pharmaceuticals, Inc. The authority of each of the attorneys-in-fact under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4 and 5 with regard to the undersigned’s ownership of or transactions in securities of Celator Pharmaceuticals, Inc., unless earlier revoked in writing. The undersigned acknowledges that none of the aforementioned attorneys-in-fact is assuming any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

Date: June 13, 2014	/s/ Joseph A. Mollica
	Joseph A. Mollica